Aridis Pharmaceuticals Inc Financials
This page shows Aridis Pharmaceuticals Inc (ARDS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Aridis still operates as a financed development program, with research spending far outweighing the revenue base that would normally support it.
By FY2022, operating cash burn of-$29.1M was about six times year-end cash of$4.9M , so the company could not fund even one year of activity internally. Combined with a 0.3x current ratio and negative equity, the balance sheet was functioning as a bridge for ongoing development work rather than as support for a self-funding commercial business.
The FY2022 net loss of
External financing kept the company operating, but it did not repair liquidity: cash fell from
Financial Health Signals
We are recalculating Aridis Pharmaceuticals Inc's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.
Aridis Pharmaceuticals Inc scores -27.23, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($4K) relative to total liabilities ($38.9M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Aridis Pharmaceuticals Inc passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
For every $1 of reported earnings, Aridis Pharmaceuticals Inc generates $0.96 in operating cash flow (-$29.1M OCF vs -$30.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Aridis Pharmaceuticals Inc generated $3.1M in revenue in fiscal year 2022. This represents an increase of 101.4% from the prior year.
Aridis Pharmaceuticals Inc's EBITDA was -$29.5M in fiscal year 2022, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 30.2% from the prior year.
Aridis Pharmaceuticals Inc reported -$30.4M in net income in fiscal year 2022. This represents an increase of 28.0% from the prior year.
Cash & Balance Sheet
Aridis Pharmaceuticals Inc generated -$29.2M in free cash flow in fiscal year 2022, representing cash available after capex. This represents a decrease of 24.5% from the prior year.
Aridis Pharmaceuticals Inc held $4.9M in cash against $0 in long-term debt as of fiscal year 2022.
Aridis Pharmaceuticals Inc had 27M shares outstanding in fiscal year 2022. This represents an increase of 52.7% from the prior year.
Margins & Returns
Aridis Pharmaceuticals Inc's operating margin was -970.3% in fiscal year 2022, reflecting core business profitability. This is up 1812.1 percentage points from the prior year.
Aridis Pharmaceuticals Inc's net profit margin was -982.6% in fiscal year 2022, showing the share of revenue converted to profit. This is up 1766.2 percentage points from the prior year.
Capital Allocation
Aridis Pharmaceuticals Inc invested $25.9M in research and development in fiscal year 2022. This represents a decrease of 29.8% from the prior year.
Aridis Pharmaceuticals Inc invested $82K in capex in fiscal year 2022, funding long-term assets and infrastructure. This represents a decrease of 84.5% from the prior year.
ARDS Income Statement
| Metric | Q3'23 | Q2'23 | Q1'23 | Q4'22 | Q3'22 | Q2'22 | Q1'22 | Q4'21 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $417K-97.9% | $19.6M+1715.8% | $1.1M-10.8% | $1.2M+204.0% | $399K+36.6% | $292K-75.4% | $1.2M | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $175K-96.3% | $4.7M-15.6% | $5.5M-21.1% | $7.0M+14.5% | $6.1M-3.6% | $6.3M-1.6% | $6.5M | N/A |
| SG&A Expenses | $1.1M-15.2% | $1.3M-27.8% | $1.8M+11.6% | $1.6M-4.0% | $1.7M+0.7% | $1.7M-22.2% | $2.2M | N/A |
| Operating Income | -$869K-106.4% | $13.7M+318.3% | -$6.3M+15.6% | -$7.4M-0.1% | -$7.4M+4.2% | -$7.7M-4.2% | -$7.4M | N/A |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | $250K | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$83K-100.7% | $12.1M+278.2% | -$6.8M-6.7% | -$6.4M+22.5% | -$8.2M-3.3% | -$8.0M-2.7% | -$7.8M | N/A |
| EPS (Diluted) | $0.00-100.0% | $0.33 | N/A | N/A | $-0.47-4.4% | $-0.45-2.3% | $-0.44 | N/A |
ARDS Balance Sheet
| Metric | Q3'23 | Q2'23 | Q1'23 | Q4'22 | Q3'22 | Q2'22 | Q1'22 | Q4'21 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $6.5M+0.8% | $6.5M-31.3% | $9.4M-35.8% | $14.7M+21.2% | $12.1M-27.4% | $16.7M-29.9% | $23.8M-11.1% | $26.8M |
| Current Assets | $4.1M+5.8% | $3.9M-40.8% | $6.6M-43.5% | $11.6M+34.6% | $8.6M-33.1% | $12.9M-34.7% | $19.8M-18.9% | $24.4M |
| Cash & Equivalents | $35K+84.2% | $19K-98.6% | $1.3M-72.9% | $4.9M+158.5% | $1.9M-70.1% | $6.3M-49.4% | $12.5M-31.1% | $18.1M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $417K+108.5% | $200K | N/A | $1.0M | N/A | $1.0M | $0 | $0 |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $18.3M-14.3% | $21.4M-42.7% | $37.3M-4.1% | $38.9M-18.8% | $47.9M+14.2% | $42.0M-3.4% | $43.5M+8.9% | $39.9M |
| Current Liabilities | $17.5M-14.3% | $20.4M-42.4% | $35.4M-4.0% | $36.9M-12.0% | $41.9M+8.5% | $38.6M+7.2% | $36.0M+8.1% | $33.3M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$11.8M+20.9% | -$14.9M+46.5% | -$27.9M-15.1% | -$24.2M+32.4% | -$35.8M-28.2% | -$27.9M-36.9% | -$20.4M-55.7% | -$13.1M |
| Retained Earnings | -$190.4M0.0% | -$190.3M+6.0% | -$202.5M-3.5% | -$195.7M-5.1% | -$186.2M-3.4% | -$180.2M-4.5% | -$172.4M-4.3% | -$165.3M |
ARDS Cash Flow Statement
| Metric | Q3'23 | Q2'23 | Q1'23 | Q4'22 | Q3'22 | Q2'22 | Q1'22 | Q4'21 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$983K+77.4% | -$4.3M-8.5% | -$4.0M+53.2% | -$8.6M-100.6% | -$4.3M+30.5% | -$6.1M+39.6% | -$10.2M-172.6% | -$3.7M |
| Capital Expenditures | N/A | N/A | N/A | $49K | $0-100.0% | $12K-42.9% | $21K+148.8% | -$43K |
| Free Cash Flow | N/A | N/A | N/A | -$8.6M-101.8% | -$4.3M+30.7% | -$6.2M+39.6% | -$10.2M-170.1% | -$3.8M |
| Investing Cash Flow | $0 | N/A | N/A | -$49K | $0+100.0% | -$12K+42.9% | -$21K-148.8% | $43K |
| Financing Cash Flow | $999K-67.0% | $3.0M+1051.3% | $263K-97.6% | $11.0M+2091.3% | -$554K-298.6% | -$139K-103.1% | $4.4M-10.3% | $5.0M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
ARDS Financial Ratios
| Metric | Q3'23 | Q2'23 | Q1'23 | Q4'22 | Q3'22 | Q2'22 | Q1'22 | Q4'21 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -208.4%-278.0pp | 69.6%+648.4pp | -578.8%+32.9pp | -611.7%+1245.9pp | -1857.6%+792.0pp | -2649.7%-2024.2pp | -625.4% | N/A |
| Net Margin | -19.9%-81.7pp | 61.8%+691.8pp | -629.9%-103.4pp | -526.6%+1538.4pp | -2064.9%+667.6pp | -2732.5%-2078.3pp | -654.3% | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -1.3%-188.6pp | 187.3%+259.6pp | -72.3%-28.8pp | -43.5%+24.5pp | -68.0%-20.2pp | -47.8%-15.2pp | -32.6% | N/A |
| Current Ratio | 0.24+0.0 | 0.190.0 | 0.19-0.1 | 0.32+0.1 | 0.21-0.1 | 0.33-0.2 | 0.55-0.2 | 0.73 |
| Debt-to-Equity | -1.55-0.1 | -1.43-0.1 | -1.34+0.3 | -1.61-0.3 | -1.34+0.2 | -1.50+0.6 | -2.13+0.9 | -3.04 |
| FCF Margin | N/A | N/A | N/A | -709.5%+359.4pp | -1068.9%+1037.6pp | -2106.5%-1248.3pp | -858.2% | N/A |
Note: Shareholder equity is negative (-$24.2M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.32), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Aridis Pharmaceuticals Inc's annual revenue?
Aridis Pharmaceuticals Inc (ARDS) reported $3.1M in total revenue for fiscal year 2022. This represents a 101.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Aridis Pharmaceuticals Inc's revenue growing?
Aridis Pharmaceuticals Inc (ARDS) revenue grew by 101.4% year-over-year, from $1.5M to $3.1M in fiscal year 2022.
Is Aridis Pharmaceuticals Inc profitable?
No, Aridis Pharmaceuticals Inc (ARDS) reported a net income of -$30.4M in fiscal year 2022, with a net profit margin of -982.6%.
What is Aridis Pharmaceuticals Inc's EBITDA?
Aridis Pharmaceuticals Inc (ARDS) had EBITDA of -$29.5M in fiscal year 2022, measuring earnings before interest, taxes, depreciation, and amortization.
What is Aridis Pharmaceuticals Inc's operating margin?
Aridis Pharmaceuticals Inc (ARDS) had an operating margin of -970.3% in fiscal year 2022, reflecting the profitability of core business operations before interest and taxes.
What is Aridis Pharmaceuticals Inc's net profit margin?
Aridis Pharmaceuticals Inc (ARDS) had a net profit margin of -982.6% in fiscal year 2022, representing the share of revenue converted into profit after all expenses.
What is Aridis Pharmaceuticals Inc's free cash flow?
Aridis Pharmaceuticals Inc (ARDS) generated -$29.2M in free cash flow during fiscal year 2022. This represents a -24.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Aridis Pharmaceuticals Inc's operating cash flow?
Aridis Pharmaceuticals Inc (ARDS) generated -$29.1M in operating cash flow during fiscal year 2022, representing cash generated from core business activities.
What are Aridis Pharmaceuticals Inc's total assets?
Aridis Pharmaceuticals Inc (ARDS) had $14.7M in total assets as of fiscal year 2022, including both current and long-term assets.
What are Aridis Pharmaceuticals Inc's capital expenditures?
Aridis Pharmaceuticals Inc (ARDS) invested $82K in capital expenditures during fiscal year 2022, funding long-term assets and infrastructure.
How much does Aridis Pharmaceuticals Inc spend on research and development?
Aridis Pharmaceuticals Inc (ARDS) invested $25.9M in research and development during fiscal year 2022.
What is Aridis Pharmaceuticals Inc's current ratio?
Aridis Pharmaceuticals Inc (ARDS) had a current ratio of 0.32 as of fiscal year 2022, which is below 1.0, which may suggest potential liquidity concerns.
What is Aridis Pharmaceuticals Inc's debt-to-equity ratio?
Aridis Pharmaceuticals Inc (ARDS) had a debt-to-equity ratio of -1.61 as of fiscal year 2022, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Aridis Pharmaceuticals Inc's return on assets (ROA)?
Aridis Pharmaceuticals Inc (ARDS) had a return on assets of -206.7% for fiscal year 2022, measuring how efficiently the company uses its assets to generate profit.
What is Aridis Pharmaceuticals Inc's cash runway?
Based on fiscal year 2022 data, Aridis Pharmaceuticals Inc (ARDS) had $4.9M in cash against an annual operating cash burn of $29.1M. This gives an estimated cash runway of approximately 2 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Aridis Pharmaceuticals Inc's debt-to-equity ratio negative or unusual?
Aridis Pharmaceuticals Inc (ARDS) has negative shareholder equity of -$24.2M as of fiscal year 2022, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Aridis Pharmaceuticals Inc's Altman Z-Score?
Aridis Pharmaceuticals Inc (ARDS) has an Altman Z-Score of -27.23, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Aridis Pharmaceuticals Inc's Piotroski F-Score?
Aridis Pharmaceuticals Inc (ARDS) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Aridis Pharmaceuticals Inc's earnings high quality?
Aridis Pharmaceuticals Inc (ARDS) has an earnings quality ratio of 0.96x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.